From: Chapter 3, Project 2: assessment of predictive value of new genetic variants
Included under terms of UK Non-commercial Government License.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Overall breast cancer risk score | Category | Median age (years) at the development of breast cancer (95% CI) | HR (95% CI) | p-value | Harrell’s C |
---|---|---|---|---|---|
18 SNPsa | Quintile 1 (highest risk) | 47.01 (44.4 to 49.98) | 1.00 (1.00) | 0.25 | 0.54 |
Quintile 2 | 46.35 (43.21 to 49.50) | 1.09 (0.75 to 1.59) | |||
Quintile 3 | 51.34 (43.89 to 63.94) | 0.85 (0.56 to 1.27) | |||
Quintile 4 | 44.33 (40.89 to 50.01) | 1.24 (0.85 to 1.80) | |||
Quintile 5 (lowest risk) | 45.46 (43.06 to 47.59) | 1.20 (0.82 to 1.75) | |||
3 SNPsb | Quintile 1 (highest risk) | 44.64 (42.35 to 47.90) | 1.00 (1.00) | 0.12 | 0.51 |
Quintile 2 | 44.50 (43.04 to 48.62) | 0.97 (0.69 to 1.36) | |||
Quintile 3 | 51.10 (41.67 to 62.50) | 0.70 (0.41 to 1.21) | |||
Quintile 4 | 48.42 (45.46 to 52.06) | 0.74 (0.54 to 1.03) | |||
Quintile 5 | 45.91 (39.38 to 54.47) | 0.94 (0.60 to 1.47) | |||
9 SNPsc | Quintile 1(highest risk) | 46.60 (44.28 to 48.62) | 1.00 (1.00) | 0.92 | 0.48 |
Quintile 2 | 45.51 (43.06 to 50.18) | 1.12 (0.77 to 1.61) | |||
Quintile 3 | 45.85 (44.05 to 54.24) | 0.83 (0.56 to 1.23) | |||
Quintile 4 | 44.31 (41.08 to 49.50) | 1.11 (0.76 to 1.62) | |||
Quintile 5 | 48.42 (43.23 to 51.90) | 0.99 (0.68 to 1.45) |
HR, hazard ratio.
Validated in a general population. ORs and RAFs taken from Turnbull et al.131
Validated in BRCA1 mutation carriers. ORs and RAFs taken from Antoniou et al.136
Three SNPs validated in BRCA1 mutation carriers and six validated in a general population but not yet validated in BRCA1 mutation carriers. ORs and RAFs for the three validated SNPs taken from Antoniou et al.136 and for the six not yet validated in BRCA1 mutation carriers taken from Turnbull et al.131
Source: reproduced with permission from Ingham SL, Warwick J, Byers H, Lalloo F, Newman WG, Evans DGR. Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK. Clinical Genetics 2013, 84:1, 37–42, © 2012 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.140
From: Chapter 3, Project 2: assessment of predictive value of new genetic variants
Included under terms of UK Non-commercial Government License.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.